Cbfa-1 (Runx-2) and osteocalcin expression by human osteoblasts in heparin osteoporosis in vitro

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 4, 2006, Pages 465-472

  Handschin, Alexander E ^a   Egermann, Marcus ^a   Trentz, Otmar ^a   Wanner, Guido A ^a   Kock, Hans Jürgen ^b   Zünd, Gregor ^a   Trentz, Omana Anna ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Hochtaunus Kliniken   (Germany)

Author keywords

Cbfa 1; Heparin osteoporosis; Osteoblast; Osteocalcin

Indexed keywords

DALTEPARIN; OSTEOCALCIN; TRANSCRIPTION FACTOR RUNX2;

ADULT; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CALCIFICATION, PHYSIOLOGIC; CELL DIVISION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA PRIMERS; HEPARIN; HUMANS; OSTEOBLASTS; OSTEOCALCIN; OSTEOPOROSIS; POLYMERASE CHAIN REACTION;

EID: 33748504532     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606293433     Document Type: Article

References (33)

1. Griffith GC, Nichols G, Asher J, et al. Heparin osteoporosis. JAMA 1965;193:91.
2. Squires JW, Pinch LW. Heparin-induced spinal fractures. JAMA 1979;241:2417.
3. Wise PH, Hall AJ. Heparin-induced osteopenia in pregnancy. BMJ 1980;281:110.
4. Megard M, Cuche M, Grapeloux A. Heparin osteoporosis: Histomorphometric analyis of bone biopsy. Nouv Presse Med. 1982;11:261.
5. Dahlmann TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168:1265.
6. Sivakumaran M, Ghosh K, Zaidi Y, et al. Osteoporosis and vertebral collapse following low-dose, low-molecular-weight heparin therapy in a young patient. Clin Lab Haematol 1996;18:55.
7. Douketis JD, Ginsberg JS, Burrows RF, et al. The effect of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996;75:254.
8. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low-molecular-weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost 1997;77:39.
9. Wawrzynska L, Tomkowski WZ, Przedlacki J, et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003;33:64.
10. Kock HJ, Handschin AE. Osteoblast growth inhibition by unfractionated and by low-molecular-weight heparins: An in-vitro investigation. Clin Appl Thromb Hemost 2002;8:251.
11. Walton KJ, Duncan JM, Deschamps P, et al. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 2002;100:2530.
12. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low-molecular-weight heparin on bone nodule formation in vitro. Thromb Hemost 1998;80:413.
13. Handschin AE, Trentz OA, Hoerstrup SP, et al. Effect of low-molecular-weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro. Br J Surg 2005;92:177.
14. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996;382:448.
15. Lian JB, Javed A, Zaidi SK, et al. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004;14:1.
16. Lian JB, Stein GS. Runx2/Cbfa1: A multifunctional regulator of bone formation. Curr Pharm Des 2003;9:2677.
17. Ducy P. Cbfa-1: A molecular switch in osteoblast biology. Dev Dyn 2000;219:461.
18. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa-1: A transcriptional activator of osteoblast differentiation. Cell 1997;89:747.
19. Trentz OA, Hoerstrup SP, Sun LK, et al. Osteoblasts response to allogenic and xenogenic solvent dehydrated cancellous bone in vitro. Biomaterials 2003;24:3417.
20. Mocellin S, Rossi CR, Pilati P, et al. Quantitative real-time PCR: A powerful ally in cancer research. Trends Mol Med 2003;9:189.
21. Prophet EB, Mills B, Arrington JB, Sobin LH, eds. Laboratory Methods in Histotechnology of the Armed Forces Institute of Pathology, 4th ed., Washington DC: American Registry of Pathology, 1992.
22. Aronow MA, Gerstenfeld LC, Owen TA, et al. Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. J Cell Physiol 1990;143:213.
23. Trentz OA, Handschin AE, Bestman L, et al. Influence of brain injury on early posttraumatic bone metabolism. Crit Care Med 2005;33:399.
24. Banerjee C, et al. Differential regulation of two principal Runx2/Cbfa-1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype. Endocrinology 2001;142:4026.
25. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa-1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755.
26. Otto F, Thornell AP, Crompton T, et al. Cbfa-1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765.
27. Liu W, Toyosawa S, Furuichi T, et al. Overexpression of Cbfa-1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001;155:157.
28. Phan TC, Xu J, Zheng MH. Interaction between osteoblast and osteoclast: Impact in bone disease. Histol Histopathol 2004;19:1325.
29. Fuller K, Chambers TJ, Gallagher AC. Heparin augments osteoclast resorption-stimulating activity in serum. J Cell Physiol 1991;147:208.
30. Hauser HJ, Brenner RE. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem 2004;91:1062.
31. Pautke C, Schieker M, Tischer T. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 2004;24:3743.
32. Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J Thromb Haemost 2003;1:896.
33. Kolb G, Bodamer I, Galster H, et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low-molecular-weight heparin Certoparin after endoprosthetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb Haemost 2003;90:1100.